Use of human data for the derivation of a reference dose for chlorpyrifos

Regulatory Toxicology and Pharmacology

Volumn 33, Issue 2, 2001, Pages 110-116

  Van Gemert, Marcia ^a   Dourson, Michael ^b   Moretto, Angelo ^c   Watson, Michael ^d  

^a Van Gemert and Hauswirth LLC   (United States)

^b Toxicology Excellence for Risk Assessment   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

^d Ricerca Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHLORPYRIFOS; CHOLINESTERASE;

ARTICLE; DATA ANALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD QUALITY; PRIORITY JOURNAL; REFERENCE VALUE; SPECIES DIFFERENCE; TOXICOLOGY;

ANIMALIA;

EID: 0035007914     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.2000.1447     Document Type: Article

References (28)

1. Amitai, G., Moorad, D., Adani, R., and Doctor, B. P. (1998). Inhibition of acetylcholinesterase and butyrylcholinesterase by chlorpyrifosoxon. Biochem. Pharmacol. 56, 293-299.
2. Barnes, D. G., and Dourson, M. L. (1988). Reference dose (RfD): Description and use in health risk assessments. Regul. Toxicol. Pharmacol. 8, 471-486.
3. Chandra, S. M., Harp, P., Liu, J., and Pope, C. N. (1995). Comparative developmental and maternal neurotoxicity following acute gestational exposure to chlorpyrifos in rats. J. Toxicol. Environ. Health 44, 189-202.
4. Chandra, S. M., and Pope, C. N. (1996). Neurochemical and neurobehavioral effects of repeated gestational exposure to chlorpyrifos in maternal and developing rats. Pharmacol. Biochem. Behav. 36(1), 346-357.
5. Chen, W. L., Sheets, J. J., Nolan, R. J., and Mattsson, J. L. (1999). Human red blood cell acetylcholinesterase inhibition as the appropriate and conservative surrogate endpoint for establishing chlorpyrifos reference dose. Regul. Toxicol. Pharmacol. 29, 15-22.
6. Clegg, D. J., and van Gemert, M. (1999). Determination of the reference dose for chlorpyrifos: Proceedings of an expert panel. J. Toxicol. Environ. Health B 2, 211-255.
7. Coulston, F., Golberg, L., and Griffin, T. (1972). Safety Evaluation of Dowco 179 in Human Volunteers. Unpublished report from the Institute of Experimental Pathology and Toxicology, Albany Medical College.
8. Deacon, M. M., Murray, J. S., Pliny, M. K., Rao, K. S., Dittenber, D. A., Hanley, T. R., Jr., and John, J. A. (1980). Embryo toxicity and feto toxicity of orally administered chlorpyrifos in mice. Toxicol. Appl. Pharmacol. 54, 31-40.
9. Dourson, M. L., and Stara, J. F. (1983). Regulatory history and experimental support of uncertainty (safety) factors. Regul. Toxicol. Pharmacol. 3, 224-238.
10. Ellman, G. L., Courtney, K. D., Andres, V., Jr., and Featherstone, R. B. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7, 88-95.
11. EPA (U.S. Environmental Protection Agency) (1999).The Integrated Risk Information System (IRIS): Online. National Center for Environmental Assessment, Washington, DC.
12. EPA (U.S. Environmental Protection Agency) (1999). Hazard Identification Assessment Review Committee (HIARC) Chlorpyrifos -Hazard Identification Based on Animal Studies, March 4, 1999.
13. EPA (U.S. Environmental Protection Agency) (1998). FIFRA Science Advisory Panel Final Document, March 1998.
14. FAO/WHO (1999) Pesticide Residues in Food, Report 153, Chlorpyrifos. World Health Organization, Geneva, Switzerland.
15. IPCS (International Programme on Chemical Safety) (1994). Environmental Health Criteria No. 170 - Assessing Human Health Risks of Chemicals: Derivation of Guidance Values for Health-Based Exposure Limits. World Health Organization, Geneva, Switzerland.
16. Kisicki, J. C., Seip, C. W., and Combs, M. L. (1999). A Rising Dose Toxicology Study to Determine the No-Observable-Effect-Levels (NOEL) for Erythrocyte Acetylcholinesterase (AChE) Inhibition and Cholinergic Signs and Symptoms of Chlorpyrifos at Three Dose Levels, Unpublished report from M. D. S. Harris.
17. Lassiter, T. L., Padilla, S., Mortensen, S. R., et al. (1998). Gestational exposure to chlorpyrifos: Apparent protection of the fetus? Toxicol. Appl. Pharmacol. 152, 56-65.
18. Lotti, M. (1995). Cholinesterase inhibition: Complexities in interpretation. Clin. Chem. 41, 1814-1818.
19. Maurissen, J. P., Hoberman, A. M., Garman, R. H., Hanley, T. R., Jr. (2000). Lack of selective developmental neurotoxicity in rat pups from dams treated by gavage with chlorpyrifos. Toxicol. Sci. 57, 250-263.
20. Mattsson, J. L., Maurissen, J. P. J., Nolan, R. J., and Brzak, K. A. (2000). Lack of differential sensitivity to cholinesterase inhibition in fetuses and neonates compared to dams treated perinatally with chlorpyrifos. Toxicol. Sci. 53, 438-446.
21. McCollister, S. B., Kociba, R. J., Humiston, C. G., McCollister, D. D., and Gehring, P. J. (1974). Studies of the acute and long-term oral toxicity of chlorpyrifos (O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphorothioate). Food Cosmet. Toxicol. 12, 45-61.
22. Meek, M. E., Newhook, R., Liteplo, R. G., and Armstrong, V. C. (1994). Approach to assessment of risk to human health for priority substances under the Canadian Environmental Protection Act. Environ. Carcinog. Ecotoxicol. Rev. C12(2), 105-134.
23. Moser, V. C., and Padilla, S. (1998). Age- and gender-related differences in the time course of behavioral and biochemical effects produced by oral chlorpyrifos in rats. Toxicol. Appl. Pharmacol. 149, 107-119.
24. Nolan, R. J., Rick, D. L., Freshour, N. L., and Saunders, J. H. (1984). Chlorpyrifos: Pharmacokinetics in human volunteers. Toxicol. Appl. Pharmacol. 73, 8-15.
25. Nordstrandt, A. C., Padilla, S., and Moser, V. C. (1997). The relationship of oral chlorpyrifos effects on behavior, cholinesterase inhibition and muscarinic receptor density in rats. Pharmacol. Biochem. Behav. 58, 15-23.
26. Pope, C. N., and Chakraborti, T. K. (1992). Dose-related inhibition of brain and plasma cholinesterase in neonatal and adult rats following sublethal organophosphate exposures. Toxicology 73, 35-43.
27. Taylor, P. (1996). Anticholinesterase agents. In Goodman & Gilman's The Pharmacological Basis of Therapeutics. (J. G. Hardpan, A. Goodman, and L. E. Limbed, Eds.), pp. 161-176. McGraw-Hill, New York.
28. Zeng, Q., Oliver, K., Won, Y., and Pope, C. (1999). Comparative cholinergic neurotoxicity of oral chlorpyrifos exposures in neonatal and adult rats. Toxicol. Sci. 48(1-S), 186. [Abstract 874]